Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design of Dry Powder Inhalers: 2. The Impact of Suboptimal Peak Inspiratory Flow Rates on Bronchodilation in Patients with Obstructive Lung Diseases.

Journal of aerosol medicine and pulmonary drug delivery·2026
Same author

Design of Dry Powder Inhalers: 1. Does Size Matter?

Journal of aerosol medicine and pulmonary drug delivery·2026
Same author

Reimagining carrier-based formulations for inhalation: Respirable agglomerates.

Journal of pharmaceutical sciences·2026
Same author

Spray-Drying Process Optimization and Modeling for an Inhaled Dry Powder of 5-Azacytidine for Treating Local and Metastatic Lung Cancer.

Molecular pharmaceutics·2025
Same author

Molecular Prosthetics and CFTR Modulators Additively Increase Secretory HCO<sub>3</sub><sup>-</sup> Flux in Cystic Fibrosis Airway Epithelia.

ACS chemical biology·2025
Same author

Preclinical assessment of pharmacokinetics and anticonvulsant activity of CBDTech, a novel orally administered cannabidiol (CBD) formulation for seizure and epilepsy.

Journal of cannabis research·2025

Related Experiment Video

Updated: Jul 16, 2026

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Spray-Dried Formulations of Relaxin-H2 for Inhalation.

Danforth P Miller1, Nani P Kadrichu2, Thomas E Tarara3

  • 1Flurry Powders, San Leandro, CA, USA.

Pharmaceutical Research
|July 14, 2026
PubMed
Summary

A novel inhaled formulation of relaxin-H2 (human relaxin-2) was developed using spray drying. This dry powder formulation allows for sustained protein concentrations, enabling chronic home administration for lung and systemic applications.

Keywords:
alberta idealized throatamorphous glasspharmacokinetics

More Related Videos

Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Related Experiment Videos

Last Updated: Jul 16, 2026

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems
  • Biotechnology

Background:

  • Relaxin-H2 is a pleiotropic hormone with potential therapeutic applications.
  • Chronic administration of protein therapeutics often requires invasive methods.
  • Developing non-invasive delivery methods for protein drugs is a significant challenge.

Purpose of the Study:

  • To create an inhaled relaxin-H2 formulation for sustained therapeutic levels.
  • To achieve protein concentrations above 10 ng/mL in serum and lung fluid for 24 hours.
  • To enable convenient, at-home chronic administration of relaxin-H2.

Main Methods:

  • Spray drying of relaxin-H2 in sodium acetate buffer to create dry powder formulations.
  • Assessment of powder physicochemical properties and aerosol performance.
  • Pharmacokinetic studies in rats and dogs following intratracheal and inhaled administration.

Main Results:

  • Spray-dried relaxin-H2 powder exhibited stability for over two years.
  • Optimized process achieved high lung delivery (>90% w/w) via a dry powder inhaler.
  • Sustained serum and lung fluid concentrations (>10 ng/mL) for 18-24 hours were observed in animal models with high bioavailability.

Conclusions:

  • Inhaled dry powder formulations of relaxin-H2 offer a promising non-invasive delivery strategy.
  • This technology facilitates chronic administration for both local lung and systemic therapeutic uses.
  • The developed formulation supports potential home-based treatment regimens.